Fourthly, of particular importance, DF-HSA exerts potent therapeutic efficacy against the K-Ras mutant MIA PaCa-2 pancreatic carcinoma xenograft in athymic mice. This evidence concerns the gene KRAS and exocrine pancreatic carcinoma.